Comparison between gradient gel electrophoresis and nuclear magnetic resonance spectroscopy in estimating coronary heart disease risk associated with LDL and HDL particle size

Clinical Chemistry

Volumn 56, Issue 5, 2010, Pages 789-798

  Arsenault, Benoit J ^a,b   Lemieux, Isabelle ^b   Després, Jean Pierre ^b,c   Wareham, Nicholas J ^d   Stroes, Erik S G ^a   Kastelein, John J P ^a   Khaw, Kay Tee ^e   Boekholdt, S Matthijs ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b LAVAL UNIVERSITY   (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

^d MRC EPIDEMIOLOGY UNIT   (United Kingdom)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION COEFFICIENT; FEMALE; GEL ELECTROPHORESIS; GRADIENT GEL ELECTROPHORESIS; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTICLE SIZE; PROSPECTIVE STUDY;

AGED; CORONARY DISEASE; ELECTROPHORESIS; FEMALE; HUMANS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PARTICLE SIZE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 77951705622     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2009.140939     Document Type: Article

References (29)

1. Lamarche B, Després JP, Moorjani S, Cantin B, Dagenais GR, Lupien PJ. Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Québec Cardiovascular Study). Am J Cardiol 1995;75:1189-1195 (Pubitemid 28487071)
2. Bloomgarden ZT. Dyslipidemia and the metabolic syndrome. Diabetes Care 2004;27:3009-3016
3. Després JP, Lemieux I, Dagenais GR, Cantin B, Lamarche B. Evaluation and management of atherogenic dyslipidemia: beyond low-density lipoprotein cholesterol. CMAJ 2001;165:1331-1333 (Pubitemid 33044063)
4. Wierzbicki AS, Mikhailidis DP. Beyond LDL-C: the importance of raising HDL-C. Curr Med Res Opin 2002;18:36-44.
5. Mudd JO, Borlaug BA, Johnston PV, Kral BG, Rouf R, Blumenthal RS, Kwiterovich PO Jr. Beyond low-density lipoprotein cholesterol: defining the role of low-density lipoprotein heterogeneity in coronary artery disease. J Am Coll Cardiol 2007;50:1735-1741 (Pubitemid 47600586)
6. Arsenault BJ, Lemieux I, Després JP, Wareham NJ, Luben R, Kastelein JJ, et al. Cholesterol levels in small LDL particles predict the risk of coronary heart disease in the EPIC-Norfolk prospective population study. Eur Heart J 2007;28:2770-2777 (Pubitemid 350135531)
7. Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Després JP. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. Circulation 1997;95:69-75.
8. Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM, Hennekens CH. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996;276:882-888 (Pubitemid 26301607)
9. Bhakdi S, Dorweiler B, Kirchmann R, Torzewski J, Weise E, Tranum-Jensen J, et al. On the pathogenesis of atherosclerosis: enzymatic transformation of human low density lipoprotein to an atherogenic moiety. J Exp Med 1995;182:1959-1971
10. Lyons TJ. Glycation and oxidation: a role in the pathogenesis of atherosclerosis. Am J Cardiol 1993;71:26B-31B.
11. van der Steeg WA, Holme I, Boekholdt SM, Larsen ML, Lindahl C, Stroes ES, et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol 2008;51:634-642
12. Pascot A, Lemieux I, Prud'homme D, Tremblay A, Nadeau A, Couillard C, et al. Reduced HDL particle size as an additional feature of the atherogenic dyslipidemia of abdominal obesity. J Lipid Res 2001;42:2007-2014
13. Watanabe H, Soderlund S, Soro-Paavonen A, Hiukka A, Leinonen E, Alagona C, et al. Decreased high-density lipoprotein (HDL) particle size, prebeta-, and large HDL subspecies concentration in Finnish low-HDL families: relationship with intima-media thickness. Arterioscler Thromb Vasc Biol 2006;26:897-902.
14. Zeller M, Masson D, Farnier M, Lorgis L, Deckert V, Pais de Barros JP, et al. High serum cholesteryl ester transfer rates and small high-density lipoproteins are associated with young age in patients with acute myocardial infarction. J Am Coll Cardiol 2007;50:1948-1955
15. Link JJ, Rohatgi A, de Lemos JA. HDL cholesterol: physiology, pathophysiology, and management.. Curr Probl Cardiol 2007;32:268-314.
16. Witte DR, Taskinen MR, Perttunen-Nio H, Van Tol A, Livingstone S, Colhoun HM. Study of agreement between LDL size as measured by nuclear magnetic resonance and gradient gel electrophoresis. J Lipid Res 2004;45:1069-1076
17. Day N, Oakes S, Luben R, Khaw KT, Bingham S, Welch A, Wareham N. EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. Br J Cancer 1999;80 Suppl 1:95-103.
18. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
19. Pérusse M, Pascot A, Després JP, Couillard C, Lamarche B. A new method for HDL particle sizing by polyacrylamide gradient gel electrophoresis using whole plasma. J Lipid Res 2001;42:1331-1334
20. Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med 2006;26:847-870 (Pubitemid 44716510)
21. Tchernof A, Lamarche B, Prud'Homme D, Nadeau A, Moorjani S, Labrie F, et al. The dense LDL phenotype: association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men. Diabetes Care 1996;19:629-637 (Pubitemid 26181112)
22. Rizzo M, Berneis K. Low-density lipoprotein size and cardiovascular risk assessment. QJM 2006;99:1-14. (Pubitemid 43124966)
23. Superko HR. Advanced lipoprotein testing and subfractionation are clinically useful. Circulation 2009;119:2383-2395
24. Blake GJ, Otvos JD, Rifai N, Ridker PM. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation 2002;106:1930-1937 (Pubitemid 35176297)
25. Ensign W, Hill N, Heward CB. Disparate LDL phenotypic classification among 4 different methods assessing LDL particle characteristics. Clin Chem 2006;52:1722-1727 (Pubitemid 44330706)
26. Blackburn P, Côté M, Lamarche B, Couillard C, Pascot A, Tremblay A, et al. Impact of postprandial variation in triglyceridemia on low-density lipoprotein particle size. Metabolism 2003;52:1379-1386 (Pubitemid 37461103)
27. Tan KC, Cooper MB, Ling KL, Griffin BA, Freeman DJ, Packard CJ, et al. Fasting and postprandial determinants for the occurrence of small dense LDL species in non-insulin-dependent diabetic patients with and without hypertriglyceridaemia: the involvement of insulin, insulin precursor species and insulin resistance. Atherosclerosis 1995;113:273-287
28. Usui S, Hara Y, Hosaki S, Okazaki M. A new on-line dual enzymatic method for simultaneous quantification of cholesterol and triglycerides in lipoproteins by HPLC. J Lipid Res 2002;43:805-814 (Pubitemid 34477908)
29. Mueller O, Chang E, Deng D, Franz T, Jing D, Kincaid R, et al. PROCAM study: risk prediction for myocardial infarction using microfluidic high-density lipoprotein (HDL) subfractionation is independent of HDL cholesterol. Clin Chem Lab Med 2008;46:490-498 (Pubitemid 351820373)